In BC, increased RNMT activity is significantly associated with the oncogenic mutation rate of PIK3CA, suggesting that RNMT-targeted therapy may have better developmental prospects for patients with PIK3CA mutations (12). This evidence concerns the gene PIK3CA and breast cancer.